Roux-en-Y gastric bypass offers better outcomes for type 2 diabetes remission than sleeve gastrectomy in obese patients.

• Patients receiving Roux-en-Y showed higher remission rates for diabetes at 1 and 3 years, with significant differences from sleeve gastrectomy.
• At 1 and 3 years, HbA1c levels were lower in the Roux-en-Y group, indicating better glycemic control.

Prioritize Roux-en-Y for patients needing effective diabetes management along with weight loss.

• Roux-en-Y also led to greater reductions in total cholesterol and LDL levels compared to sleeve gastrectomy.